DISEASE IMPACT AND COST-EFFECTIVENESS OF A NEW DENGUE VACCINE TAK003 IN THAILAND

被引：0
|
作者：
Shen, J. [1 ]
Kharitonova, E. [2 ]
Biswal, S. [3 ]
Sharma, M. [4 ]
Aballea, S. [2 ]
Tytula, A. [5 ]
Zawieja, J. [5 ]
Towle, P. [6 ]
Hanley, R. [1 ]
机构：
[1] Takeda Int AG, Payer Value & Access, Zurich, Switzerland
[2] Creativ Ceut, HEOR, Paris, France
[3] Takeda Vaccines Inc, Clin Dev, Cambridge, MA USA
[4] Takeda Vaccines Inc, Vaccine Res & Analyt, Cambridge, MA USA
[5] Creativ Ceut, HEOR, Krakow, Poland
[6] Takeda Pharmaceut Asia Pacific Pte Ltd, Market Access, Singapore, Singapore
来源：
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES | 2023年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：S141 / S141
页数：1
相关论文
共 50 条
  • [21] Immunogenicity, Safety and Efficacy of the Dengue Vaccine TAK-003: A Meta-Analysis
    Flacco, Maria Elena
    Bianconi, Alessandro
    Cioni, Giovanni
    Fiore, Matteo
    Calo, Giovanna Letizia
    Imperiali, Gianmarco
    Orazi, Vittorio
    Tiseo, Marco
    Troia, Anastasia
    Rosso, Annalisa
    Manzoli, Lamberto
    [J]. VACCINES, 2024, 12 (07)
  • [22] A new dengue vaccine (TAK-003) now WHO recommended in endemic areas; what about travellers?
    Freedman, David O.
    [J]. JOURNAL OF TRAVEL MEDICINE, 2023, 30 (07)
  • [23] Cost-effectiveness and budget impact analyses of dengue vaccination in Indonesia
    Suwantika, Auliya Abdurrohim
    Supadmi, Woro
    Ali, Mohammad
    Abdulah, Rizky
    [J]. PLOS NEGLECTED TROPICAL DISEASES, 2021, 15 (08):
  • [24] Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults
    Inge LeFevre
    Lulu Bravo
    Nicolas Folschweiller
    Eduardo Lopez Medina
    Edson Duarte Moreira
    Francesco Nordio
    Mayuri Sharma
    Leslie M. Tharenos
    Vianney Tricou
    Veerachai Watanaveeradej
    Peter J. Winkle
    Shibadas Biswal
    [J]. npj Vaccines, 8
  • [25] An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand
    Dilokthornsakul, Piyameth
    Kengkla, Kirati
    Saokaew, Surasak
    Permsuwan, Unchalee
    Techasaensiri, Chonnamet
    Chotpitayasunondh, Tawee
    Chaiyakunapruk, Nathorn
    [J]. VACCINE, 2019, 37 (32) : 4551 - 4560
  • [26] Role of the dengue vaccine TAK-003 in an outbreak response: Modeling the Sri Lanka experience
    Fernando, LakKumar
    Kastner, Randee
    Wickramasinghe, Pujitha
    Fernando, Asvini D.
    Gunasekera, Dulanie
    Nguyen, Van Hung
    Liu, Mengya
    LeFevre, Inge
    Wallace, Derek
    Folschweiller, Nicolas
    Biswal, Shibadas
    [J]. PLOS NEGLECTED TROPICAL DISEASES, 2024, 18 (08):
  • [27] Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults
    LeFevre, Inge
    Bravo, Lulu
    Folschweiller, Nicolas
    Medina, Eduardo Lopez
    Moreira, Edson Duarte
    Nordio, Francesco
    Sharma, Mayuri
    Tharenos, Leslie M.
    Tricou, Vianney
    Watanaveeradej, Veerachai
    Winkle, Peter J.
    Biswal, Shibadas
    [J]. NPJ VACCINES, 2023, 8 (01)
  • [28] COST-EFFECTIVENESS OF PNEUMOCOCCAL VACCINE
    RANGO, N
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1981, 304 (02): : 117 - 117
  • [29] COST-EFFECTIVENESS OF FLU VACCINE
    不详
    [J]. CONNECTICUT MEDICINE, 1982, 46 (10) : 607 - 607
  • [30] COST-EFFECTIVENESS OF PNEUMOCOCCAL VACCINE
    LEVY, E
    [J]. REVUE D EPIDEMIOLOGIE ET DE SANTE PUBLIQUE, 1981, 29 (02): : 133 - 153
12345